Showing 471-480 of 650 results for "".
- Survey: More than Half of Americans Seek Skin Care and Other Products Aligned with Sustainable Lifestyleshttps://practicaldermatology.com/news/survey-more-half-americans-seek-skin-care-and-other-products-aligned-sustainable-lifestyles/2462882/A recent consumer sentiment survey showed that over half of Americans are inclined to try new products (including those for skin care) marketed as aligned with healthier and more sustainable lifestyles. The survey
- EPI Health Issues Voluntary Recall of Several Products Following Bankruptcyhttps://practicaldermatology.com/news/epi-health-issues-voluntary-recall-several-products-following-bankruptcy/2462869/EPI Health (Novan) is initiating a voluntary recall of various within-expiry human drug products as a result of the closures and discontinuation of the post-marketing quality, regulatory and pharmacovigilance activities for these marketed products. The moves comes after EPI filed Chapter 7 bankru
- UCB Receives European Approval for Hidradenitis Suppurativa Treatment Bimzelxhttps://practicaldermatology.com/news/ucb-receives-european-approval-hidradenitis-suppurativa-treatment-bimzelx/2462815/The European Commission has granted marketing authorization for UCB’s Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy.1 Bimzelx is the first IL-17A and IL-17F bi
- Palm Phytonutrients To Be Displayed at Expohttps://practicaldermatology.com/news/palm-phytonutrients-be-displayed-expo/2462663/As the cosmeceutical market continues to expand, so does consumer interest in learning more about the key active ingredients in cosmeceutical products and how they work, according to a press release from palm phytonutrient manufacturer PhytoGaia. PhytoGaia, a manufacturer of palm phytonut
- Intravenous Ertapenem Shows Improvement in Hidradenitis Suppurativahttps://practicaldermatology.com/news/intravenous-ertapenem-for-hidradenitis-suppurativa-efficacy-and-patient-satisfaction/2462245/Results from a new analysis indicated that intravenous ertapenem was associated with improvements in markers of hidradenitis suppurativa (HS) and was linked with increased patient satisfaction. The retrospective analysis included medical records of 98 patients with HS who
- Shmuel Gov Named COO of Strata Skin Scienceshttps://practicaldermatology.com/news/shmuel-gov-named-coo-at-strata-skin-sciences/2462169/Shmuel Gov is the new Chief Operating Officer (COO) of STRATA Skin Sciences. The Company has also hired Dr. Amandeep Kaur as Vice President of Marketing and Business Growth. Mr. Gov brings more than 30 years of industry experience in medical device business, operations, and R&
- Meet Sentient’s Newest Executives...https://practicaldermatology.com/news/meet-sentients-newest-executives/2462094/Brian Kirk is Sentient’s new Chief Marketing Officer (CMO), and Jennifer Redmond joins as Chief Revenue Officer (CRO). Mr. Kirk is charged with elevating Sentient's marketing investment to support Tixel by Sentient and Sentient Sculpt, while advancing the
- Industry Vet Brent Hauser Named President, International at Cuterahttps://practicaldermatology.com/news/industry-vet-brent-hauser-named-president-international-at-cutera/2462034/Brent Hauser is the new President, International, at Cutera, Inc. Mr. Hauser will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for commercial performance in existing international markets, expansion into new geographies, and the inter
- Encouraging Preclinical Results Seen for Scinai’s NanoAbs in Plaque Psoriasishttps://practicaldermatology.com/news/encouraging-preclinical-results-seen-for-scinais-nanoabs-in-plaque-psoriasis/2462006/Scinai Immunotherapeutics Ltd.’s anti‑interleukin 17 (IL‑17) NanoAbs downregulated key molecular markers that are overexpressed in plaque psoriasis, according to preclinical data relased by Scinai. Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-
- FDA Clears Sofwave’s SUPERB Technology for Treating Acne Scarshttps://practicaldermatology.com/news/fda-clears-sofwaves-superb-technology-for-treating-acne-scars/2461969/The U.S. Food and Drug Administration (FDA) has cleared Sofwave’s SUPERB technology for treating acne scars. “Gaining FDA clearance to market SUPERB for the treatment of acne scarring not only paves the way to positively impact patients seeking improved appearances